Novo Nordisk (NVO) P/E (2014 - 2026)
Novo Nordisk (NVO) P/E from Dec 31, 2014 to Jul 21, 2026. The TTM Novo Nordisk (NVO) P/E is 11.52. You can export chart.
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
P/E
Annual P/E change of Novo Nordisk (NVO)
| Year | P/E | Change |
|---|---|---|
| 2026 | 11.52 | -19.72% |
| 2025 | 14.35 | -45.59% |
| 2024 | 26.36 | -38.48% |
| 2023 | 42.85 | +4.97% |
| 2022 | 40.83 | +18.34% |
| 2021 | 34.50 | +37.37% |
| 2020 | 25.11 | +6.32% |
| 2019 | 23.62 | +28.91% |
| 2018 | 18.32 | -20.69% |
| 2017 | 23.10 | +41.95% |
| 2016 | 16.28 | -44.46% |
| 2015 | 29.31 | -72.00% |
| 2014 | 104.67 | N/A |
Comparison Novo Nordisk (NVO) P/E with competitors
Novo Nordisk (NVO) P/E is 11.52.
| Ticker | Name | P/E | Upside |
|---|---|---|---|
| GRFS | Grifols SA | 10.11 | -12.21% |
| PFE | Pfizer Inc | 11.65 | +1.20% |
| GSK | GSK Plc | 12.10 | +5.10% |
| SNY | Sanofi | 12.12 | +5.28% |
| BMY | Bristol-Myers Squibb Company | 13.82 | +20.00% |
| OGN | Organon & Company | 14.33 | +24.41% |
| BIIB | Biogen Inc | 17.41 | +51.14% |
| GILD | Gilead Sciences Inc | 17.75 | +54.09% |
| JNJ | Johnson & Johnson | 22.09 | +91.80% |
| AMGN | AMGEN Inc | 24.75 | +114.93% |
| MRK | Merck & Co Inc | 26.93 | +133.82% |
| AZN | Astrazeneca plc | 28.44 | +146.98% |
| LLY | Lilly(Eli) & Company | 48.44 | +320.65% |
| ABBV | Abbvie Inc | 139.08 | +1107.70% |